Avidity Biosciences (RNA) Stock Price, News & Analysis

Company Overview

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study. Preclinical programs include additional neuromuscular indications such as Duchenne muscular dystrophy (DMD) and X-linked myotubular myopathy (XLMTM). Avidity’s research efforts focus on optimizing conjugate design, antibody selection, and oligonucleotide chemistries to maximize tissue uptake and therapeutic potency.

Avidity Biosciences was founded in 2017 by a team of scientists and entrepreneurs with expertise in antibody engineering, oligonucleotide chemistry and muscle biology. The company went public on the Nasdaq Global Market under the ticker RNA in January 2021. Laurent Fischer, M.D., serves as Chief Executive Officer, drawing on his background in immunology and drug discovery to guide the company’s strategic and clinical initiatives. Avidity maintains research and development operations in the United States and engages in collaborations to expand the reach of its AOC technology.

Building on its foundational platform, Avidity continues to advance multiple pipeline candidates through preclinical and clinical stages, while exploring partnership opportunities with biopharmaceutical companies. The company’s long-term objective is to transform the treatment landscape for patients with genetic muscle disorders by delivering precision RNA therapies with improved safety, efficacy and convenience.

Key Stats

• Today's Range: $44.28 to $47.17
• 50-Day Range: $34.56 to $50.36
• 52-Week Range: $21.51 to $56.00
• Volume: 990,458 shs
• Average Volume: 2.08 million shs
• Market Capitalization: $6.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $68.32
• Consensus Rating: Buy

Avidity Biosciences Stock Analysis - MarketRank™

Avidity Biosciences scored higher than 50% of companies evaluated by MarketBeat, and ranked 612th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Avidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.05, and is based on 18 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Avidity Biosciences has a consensus price target of $68.32, representing about 50.8% upside from its current price of $45.32.

Amount of Analyst Coverage

Avidity Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avidity Biosciences is -12.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avidity Biosciences is -12.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Avidity Biosciences has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.24% of the outstanding shares of Avidity Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Avidity Biosciences has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Avidity Biosciences has recently increased by 26.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avidity Biosciences does not currently pay a dividend.

Dividend Growth

Avidity Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.24% of the outstanding shares of Avidity Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Avidity Biosciences has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Avidity Biosciences has recently increased by 26.58%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.41

News Sentiment

Avidity Biosciences has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Avidity Biosciences this week, compared to 9 articles on an average week.

Search Interest

Only 17 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.

MarketBeat Follows

6 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,904,454.00 in company stock.

Percentage Held by Insiders

Only 3.83% of the stock of Avidity Biosciences is held by insiders.

RNA Stock Analysis - Frequently Asked Questions

How have RNA shares performed this year?

Avidity Biosciences' stock was trading at $29.08 at the beginning of 2025. Since then, RNA shares have increased by 55.8% and is now trading at $45.3150.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) issued its earnings results on Thursday, May, 8th. The biotechnology company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by $0.02. The biotechnology company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.63 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 33.45% and a negative net margin of 4,247.77%.

When did Avidity Biosciences IPO?

Avidity Biosciences (RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

Who are Avidity Biosciences' major shareholders?

Top institutional investors of Avidity Biosciences include Praxis Investment Management Inc.. Insiders that own company stock include Sarah Boyce, Teresa Mccarthy, Michael F Maclean, W Michael Flanagan, Eric Mosbrooker, Troy Edward Wilson, Kathleen P Gallagher, John B Moriarty, Steven George Hughes, Arthur A Levin and Tamar Thompson.
View institutional ownership trends.

How do I buy shares of Avidity Biosciences?

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Eli Lilly and Company (LLY), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 10/03/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNA
• CIK: 1599901
• Web: www.aviditybiosciences.com
• Phone: 858-401-7900
• Fax: N/A
• Employees: 190
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Avidity Biosciences: $68.32
• High Price Target: $96.00
• Low Price Target: $50.00
• Potential Upside/Downside: +54.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.05
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$322.30 million
• Net Margins: -4,247.77%
• Pretax Margin: -4,247.76%
• Return on Equity: -33.45%
• Return on Assets: -30.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.26
• Quick Ratio: 9.26

Sales & Book Value

• Annual Sales: $10.73 million
• Price / Sales: 600.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.94 per share
• Price / Book: 3.70

Miscellaneous

• Outstanding Shares: 145,903,000
• Free Float: 140,315,000
• Market Cap: $6.45 billion
• Optionable: Optionable
• Beta: 0.97